The MedTech Forum 2026: Why MedTech’s Next Conversation Is Commercial Execution

Ahead of The MedTech Forum 2026 in Stockholm, Vamstar explores why the next phase of MedTech growth will depend not only on innovation, but on the ability to execute across pricing, market access, contracts and evidence management.

In Stockholm, the agenda will be innovation. In every boardroom, the question is execution.

When delegates take their seats at The MedTech Forum 2026 in Stockholm from 11–13 May, the official program will read the way MedTech programs have read for years: innovation, digital health, AI, regulation, access to care, sustainability. These are the right themes. They reflect where the sector is moving and where the pressure is building. MedTech Europe convenes the Forum as Europe’s largest health and medical technology industry conference, drawing executives, policymakers, healthcare professionals and investors from across the continent.

But beneath the headline themes, a sharper question has taken hold of the industry. It is the question most likely to decide who leaves Stockholm with momentum, and who leaves with another set of unfinished initiatives.

How do MedTech companies actually execute in this environment?

Because the pressure on the sector is no longer isolated to one function. It is no longer just a regulatory challenge, a pricing challenge, a procurement challenge or an innovation challenge. It is all of them, at once.

MedTech companies are being asked to innovate faster, prove value earlier, comply with more demanding regulatory and data requirements, respond to more sophisticated procurement criteria, absorb cost volatility, manage sustainability expectations, and protect margins in markets that are becoming harder to navigate.

The industry does not lack ambition. It lacks operational bandwidth.

That is why the most consequential conversations in Stockholm may not be about what comes next for MedTech innovation. They will be about how MedTech organizations build the commercial infrastructure to act on it.

AI is moving from experiment to execution

Artificial intelligence will inevitably dominate the agenda at The MedTech Forum 2026. Across the industry, AI is moving beyond the laboratory, the clinical setting and the innovation showcase. It is becoming part of how companies plan, price, bid, contract, evidence and commercialize.

The recent industry commentary reflects that shift. IQVIA’s 2026 MedTech outlook points to AI, real-world evidence, medical device regulation, diagnostics, robotics and digital health as defining forces for the year ahead. ZS has gone further, framing 2026 as an inflection point where agentic AI begins moving “from the lab to the line” — executing across core MedTech value streams rather than supporting isolated tasks.

That distinction matters more than most leaders are willing to admit out loud.

For years, AI conversations in MedTech have focused on invention: better diagnostics, smarter devices, improved imaging, accelerated R&D, more personalized care. These remain critical. But the next phase of AI adoption will be judged by something less glamorous and more consequential — whether it can help MedTech businesses operate better.

Can AI help commercial teams identify the right contract opportunities earlier? Can it qualify complex RFPs against product, regulatory, pricing and evidence requirements? Can it help pricing teams see where margin is leaking? Can it surface contractual escalation rights before the window to act closes? Can it structure evidence for value-based procurement, sustainability scoring and market access? Can it connect workflows that today live across email inboxes, spreadsheets, portals, local teams and disconnected systems?

This is where the AI conversation becomes practical, and where many MedTech AI strategies quietly run aground.

The question is no longer whether AI has potential in MedTech. The question is whether companies can embed AI into the commercial operating model with enough governance, context and domain understanding to make it useful at the moments that matter.

Access has become an evidence problem

Access to care is one of the Forum’s stated themes — and rightly so. But for MedTech suppliers, access is increasingly tied to a more specific commercial discipline: producing the right evidence at the right moment.

The old commercial playbook was built around product performance, clinical differentiation and relationship-led selling. Those still matter. But buyers are now asking broader questions, and they are asking them on tighter timelines.

What is the total cost of ownership? How does this device support pathway efficiency? What outcomes evidence supports the claim? How does the solution perform across different care settings? What sustainability evidence can you provide? What cybersecurity, data governance and resilience assurances are in place? What post-award reporting can you support?

This is the direction of travel in procurement and market access. Value-based procurement is becoming more visible, more structured and more consequential. In the UK, the Department of Health and Social Care has been advancing value-based procurement guidance for MedTech, with NHS trusts piloting the approach and wider rollout expected. Healthcare procurement commentary for 2026 increasingly points to sustainability and value-based procurement as the lens through which lifecycle costs, maintenance, end-of-life impact and broader value considerations will shape sourcing decisions.

This creates a new burden — and a new test — for commercial teams.

It is no longer enough to have evidence somewhere in the organization. It has to be findable, structured, current, localized and connected to the claims being made in bids, dossiers and buyer conversations.

For most companies, that is still a meaningful gap.

Evidence sits across fragmented systems, old submissions, PDFs, market access materials, clinical repositories, sustainability reports, regulatory documents and local-market files. The result is duplication, inconsistency and slow response cycles — at exactly the moment when procurement timelines are tightening, buyer requirements are expanding, and internal review cycles are growing more complex.

This is why evidence management is no longer an administrative task. It is a commercial capability — and increasingly, a competitive one.

Regulation, cybersecurity and data governance have become trust factors

Regulatory development is another core theme for MedTech Forum 2026. But the commercial implications are often understated.

Regulation no longer sits neatly at the end of the process as a compliance checkpoint. It increasingly shapes market access, buyer confidence, procurement eligibility and commercial speed. Industry commentary for 2026 points to regulatory convergence and change, particularly around software, AI-enabled medical devices, quality systems and data foundations. Cybersecurity is following the same trajectory. For connected devices, digital health solutions and software-enabled products, cybersecurity has moved from a technical control to part of the trust architecture buyers expect to see before adoption is even on the table.

The same is true for AI governance.

As AI moves into commercial workflows, MedTech companies will need to demonstrate that outputs are explainable, evidence-linked and controlled. A generated contract response, pricing recommendation, market access summary or contract interpretation cannot be a black box. It has to be traceable to source evidence, reviewed by accountable teams, and governed through a process that withstands procurement and regulatory scrutiny.

This is where many AI initiatives stall.

The technology may work in a demo. It may produce impressive outputs in a controlled setting. But once it enters a regulated commercial environment, the requirements change entirely. The organization needs permissions, auditability, human-in-the-loop review, workflow integration, data controls and domain-specific understanding.

That is why MedTech AI implementation cannot be treated as a generic software deployment. It has to be engineered around the way the business actually works — and around the regulatory weather it actually operates in.

Sustainability is moving into commercial scoring

Sustainability will also feature prominently in Stockholm. But the commercial shift is more specific than broad ESG ambition.

Sustainability is moving into procurement. It is becoming part of supplier evaluation, contract scoring, lifecycle assessment and buyer risk management. That changes the nature of the work.

MedTech companies need more than sustainability statements. They need procurement-grade evidence: product-level information, lifecycle data, supply chain documentation, packaging details, service models, waste reduction claims, carbon impact, and proof of alignment with each buyer’s specific requirements.

For global organizations, this becomes more complex still. Sustainability expectations vary by market, buyer type and procurement framework. What is sufficient for one contract may be inadequate for another. What is useful at corporate level may not translate into a buyer-ready evidence pack.

The companies that perform in this environment will be those that turn sustainability from a reporting function into a commercial asset — connecting sustainability evidence to contract requirements, product claims, market access narratives and post-award commitments, and ensuring teams can reuse validated evidence rather than recreating it under deadline pressure.

Margin pressure is rewriting the case for commercial intelligence

The MedTech sector is operating in a more volatile cost environment than it has in a decade. Supply chain disruption, inflation, energy costs, logistics pressure, tariff exposure and geopolitical uncertainty are all making margin protection harder — and the levers to defend margin less obvious.

This is where commercial intelligence becomes critical.

Many MedTech organizations already hold contractual mechanisms that could support margin recovery: price escalation clauses, renegotiation triggers, indexation rights, volume commitments, service-level provisions, change-of-law clauses. But those rights are buried across thousands of agreements, contract documents, framework contracts and local amendments.

Knowing those rights exist is not the same as being able to act on them.

By the time teams manually search for the relevant clause, validate the trigger condition, gather supporting evidence and prepare a buyer engagement pack, the commercial window has often already narrowed — sometimes closed.

This is one of the clearest cases for moving AI into the contract stack.

The opportunity is not simply to store contracts more efficiently. It is to read them, classify them, monitor them, and connect them to commercial action. Which agreements contain escalation rights? Which markets are exposed? Which clauses are active? Which buyer conversations need to happen now? What evidence is required to support the request?

In a margin-constrained environment, speed to insight becomes speed to recovery. The companies that find that speed first will compound the advantage quietly, contract by contract, quarter by quarter.

The next MedTech operating model will be built around connected commercial execution

Taken together, the major themes around The MedTech Forum 2026 point to a single conclusion that the official agenda only hints at.

The next MedTech operating model will not be built around isolated digital projects. It will be built around connected commercial execution.

That means pricing, bidding, contracting, market access, evidence management, regulatory intelligence and sustainability proof can no longer operate as disconnected workstreams. They are increasingly part of the same commercial system.

A contract response may now require pricing discipline, product matching, regulatory eligibility, sustainability evidence, value claims, cybersecurity documentation and local market intelligence — drawn together inside a window measured in days.

A market access strategy may require policy monitoring, evidence mapping, buyer segmentation, reimbursement intelligence and competitor activity — refreshed continuously, not once a quarter.

A pricing decision may depend on contract history, contract obligations, local market dynamics, competitor benchmarks and margin exposure — all visible at the same moment, to the same team.

A contract review may surface rights that directly affect revenue protection — but only if the right clauses can be found in time.

This is where AI creates real value. Not as a layer of automation hovering above the business, but as an operating layer embedded inside the workflows that determine commercial performance.

At Vamstar, this is the problem we are focused on.

Our work with MedTech, pharmaceutical and life sciences organizations is centred on helping commercial teams turn fragmented data, documents and market signals into structured action. Through Polaris AI, Vamstar supports organizations across contract and RFP management, pricing intelligence, contract visibility, value and market access evidence, and forward-deployed engineering for the complex operational environments that define this industry.

The goal is not to replace expert teams. It is to give them the intelligence, workflow control and evidence infrastructure they need to move faster, with greater confidence, against opponents and timelines that are not slowing down.

What we expect to discuss in Stockholm

As Vamstar’s team joins industry leaders at The MedTech Forum 2026, we expect the most valuable conversations to sit at the intersection of innovation and execution:

How do MedTech companies move AI from pilots into governed workflows? How do commercial teams respond to more complex contract and procurement requirements? How can pricing, contracting and evidence functions operate from a shared intelligence layer? How do organizations prepare for value-based procurement at scale? How can sustainability, cybersecurity and regulatory evidence be made commercially usable, not just compliant? How do companies protect margin when commercial rights are hidden across fragmented contract portfolios?

These are not abstract questions. They are already shaping how MedTech companies compete — and they will shape who wins the next five years of the industry.

The organizations that succeed in the next phase of MedTech will not simply be those with the strongest products or the most ambitious innovation strategies. They will be the companies able to convert complexity into execution.

That means knowing where the opportunity is. Knowing what the buyer is asking for. Knowing what evidence supports the claim. Knowing which price corridors are defensible. Knowing which contracts contain commercial rights. Knowing which workflows need human judgement and which can be accelerated through AI.

The future of MedTech will still be shaped by innovation. But the winners will be the companies that can operationalize it.

That is the conversation we are looking forward to having in Stockholm.